According to the Complaint, Chembio Diagnostics, Inc. purports to be a leading point-of-care (POC) diagnostics company focused on detecting and diagnosing infectious diseases. The Company claims its patented Dual Path Platform (DPP) technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

According to the Complaint, Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company that uses its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention.

According to the Complaint, Enphase Energy, Inc. is a global energy technology company that “deliver[s] smart, easy-touse solutions that manage solar generation, storage and communication on one intelligent platform.” The Company asserts that it “revolutionized the solar industry with [its] microinverter technology” and that it “produce[s] a fully integrated solar-plus-storage solution.”

According to the Complaint, ProAssurance Corporation is one of the largest medical liability insurance providers in the United States.

According to the Complaint, SB One Bancorp is the holding company for SB One Bank, a full-service, commercial bank that operates regionally with eighteen branch locations in New Jersey and New York. In addition to its branches and loan production offices, SB One Bank offers a full service insurance agency, SB One Insurance Agency, Inc., and wealth services through SB One Wealth.

According to the Complaint, Co-Diagnostics, Inc. owns proprietary technology that enables it to do DNA testing for diagnostic purposes.

According to the Complaint, Wells Fargo & Company is a financial services company that provides a range of products and services, including banking, insurance, investments, mortgage, leasing, credit cards, and consumer finance. The Company operates through physical stores, the internet, and other distribution channels worldwide.

According to the Complaint, Kandi Technologies Group, Inc. through its subsidiaries, designs, produces, manufactures, and distributes electric vehicles (EVs) products, EV parts, and off-road vehicles in the People's Republic of China and internationally.

According to the Complaint, Forescout Technologies, Inc. provides “security at first sight” by delivering software that enables device visibility and control that enables enterprises and government agencies to gain improved situational awareness of their environment (devices on their networks) and orchestrate actions to reduce cyber and operational risk.

According to the Complaint, Hebron Technology Co., Ltd. conducts equipment and engineering service operations focusing on the research, development and manufacture of fluid equipment including valves, pipe fittings and others. Since July 2019, the Company has also provided financial advisory service operations.

According to the Complaint, KLX Energy Services Holdings, Inc. is a leading U.S. onshore provider of mission critical oilfield services focused on completion, intervention, and production activities for the most technically demanding wells.

According to the Complaint, Wells Fargo is a diversified financial services company that provides banking, investment, mortgage, and consumer and commercial finance products and services to individuals, businesses, and institutions in the U.S. and internationally.

According to the Complaint, Qiagen N.V. is the leading global provider of Sample to Insight solutions that enable customers to gain molecular insights from samples. The Company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

According to the Complaint, Portola Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions.

According to the Complaint, Carnival Corporation bills itself as the world’s largest leisure travel company and the largest cruise company, carrying nearly 45 percent of global cruise guests. The Company has operations in North America, Australia, Europe and Asia, operating a portfolio of global, regional and national cruise brands that sell tailored cruise products, services and vacation experiences on 104 cruise ships to destinations around the world.

According to the Complaint, Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, and metabolic and infectious diseases. On May 8, 2020, Sorrento announced a collaboration with Mount Sinai Health System for the purpose of “generat[ing] antibody products that would act as a ‘protective shield’ against SARSCoV-2 coronavirus infection, potentially blocking and neutralizing the activity of the virus in naïve at-risk populations as well as recently infected individuals.”

According to the Complaint, Colony Capital, Inc. is a leading global investment management firm with assets under management of $55 billion. The Company manages capital on behalf of its stockholders, as well as institutional and retail investors in private funds, and traded and non-traded real estate investment trusts.

According to the Complaint, Hamilton Beach Brands Holding Co., together with its subsidiaries, designs, markets, and distributes small electric household and specialty housewares appliances. The Company sells its products through a network of mass merchandisers, e-commerce retailers, national department stores, variety and drug store chains, specialty home retailers, distributors, and other retail outlets.

According to the Complaint, Taubman Centers, Inc. is an S&P MidCap 400 Real Estate Investment Trust engaged in the ownership, management, and/or leasing of twenty-six regional, super-regional, and outlet shopping centers in the United States and Asia.

According to the Complaint, CytomX Therapeutics operates as an oncology-focused biopharmaceutical company in the U.S. The Company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. CytomX’s lead product candidates in the clinical stage include, among others, CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; and CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target.